Involvement of CYP4F2 in the Metabolism of a Novel Monophosphate Ester Prodrug of Gemcitabine and Its Interaction Potential In Vitro

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2018 May 19

PMID 29772747

Citations 5

Authors

Yedong Wang

Yuan Li

Jia Lu

Huixin Qi

Isabel Cheng

Hongjian Zhang

Affiliations

Soon will be listed here.

Abstract

Compound- is an oral monophosphate prodrug of gemcitabine. Previous data showed that Compound- was more potent than gemcitabine and it was orally active in a tumor xenograft model. In the present study, the metabolism of Compound- was investigated in several well-known in vitro matrices. While relatively stable in human and rat plasma, Compound- demonstrated noticeable metabolism in liver and intestinal microsomes in the presence of NADPH and human hepatocytes. Compound- could also be hydrolyzed by alkaline phosphatase, leading to gemcitabine formation. Metabolite identification using accurate mass- and information-based scan techniques revealed that Compound- was subjected to sequential metabolism, forming alcohol, aldehyde and carboxylic acid metabolites, respectively. Results from reaction phenotyping studies indicated that cytochrome P450 4F2 (CYP4F2) was a key CYP isozyme involved in Compound- metabolism. Interaction assays suggested that CYP4F2 activity could be inhibited by Compound- or an antiparasitic prodrug pafuramidine. Because CYP4F2 is a key CYP isozyme involved in the metabolism of eicosanoids and therapeutic drugs, clinical relevance of drug-drug interactions mediated via CYP4F2 inhibition warrants further investigation.

Citing Articles

Unveiling novel genetic variants in 370 challenging medically relevant genes using the long read sequencing data of 41 samples from 19 global populations.

Ji Y, Zhao J, Gong J, Sedlazeck F, Fan S Mol Genet Genomics. 2024; 299(1):65.

PMID: 38972030 DOI: 10.1007/s00438-024-02158-x.

Computational analysis of missense variant CYP4F2*3 (V433M) in association with human CYP4F2 dysfunction: a functional and structural impact.

Farajzadeh-Dehkordi M, Mafakher L, Samiee-Rad F, Rahmani B BMC Mol Cell Biol. 2023; 24(1):17.

PMID: 37161313 PMC: 10170697. DOI: 10.1186/s12860-023-00479-0.

Prodrugs of Nucleoside 5'-Monophosphate Analogues: Overview of the Recent Literature Concerning their Synthesis and Applications.

Roy B, Navarro V, Peyrottes S Curr Med Chem. 2022; 30(11):1256-1303.

PMID: 36093825 DOI: 10.2174/0929867329666220909122820.

Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses.

Wang P, Zhang C, Li W, Zhai B, Jiang X, Reddy S Cell Commun Signal. 2020; 18(1):34.

PMID: 32122386 PMC: 7053133. DOI: 10.1186/s12964-020-0522-4.

Molecular Functionality of Cytochrome P450 4 (CYP4) Genetic Polymorphisms and Their Clinical Implications.

Jarrar Y, Lee S Int J Mol Sci. 2019; 20(17).

PMID: 31480463 PMC: 6747359. DOI: 10.3390/ijms20174274.

References

Jordheim L, Durantel D, Zoulim F, Dumontet C . Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013; 12(6):447-64. DOI: 10.1038/nrd4010. View

Tilson H, Hines L, McEvoy G, Weinstein D, Hansten P, Matuszewski K . Recommendations for selecting drug-drug interactions for clinical decision support. Am J Health Syst Pharm. 2016; 73(8):576-85. PMC: 5064943. DOI: 10.2146/ajhp150565. View

Jin Y, Zollinger M, Borell H, Zimmerlin A, Patten C . CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2010; 39(2):191-8. DOI: 10.1124/dmd.110.035378. View

Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E . FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol. 1999; 39(9):899-910. DOI: 10.1177/00912709922008515. View

Slusarczyk M, Lopez M, Balzarini J, Mason M, Jiang W, Blagden S . Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem. 2014; 57(4):1531-42. DOI: 10.1021/jm401853a. View

Andersson R, Aho U, Nilsson B, Peters G, Pastor-Anglada M, Rasch W . Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol. 2009; 44(7):782-6. DOI: 10.1080/00365520902745039. View

Edson K, Prasad B, Unadkat J, Suhara Y, Okano T, Guengerich F . Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry. 2013; 52(46):8276-85. PMC: 3900248. DOI: 10.1021/bi401208m. View

Sinokrot H, Smerat T, Najjar A, Karaman R . Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years. Molecules. 2017; 22(10). PMC: 6151663. DOI: 10.3390/molecules22101736. View

Moysan E, Bastiat G, Benoit J . Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications. Mol Pharm. 2012; 10(2):430-44. DOI: 10.1021/mp300370t. View

10.

Wickremsinhe E, Bao J, Smith R, Burton R, Dow S, Perkins E . Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure. Pharmaceutics. 2013; 5(2):261-76. PMC: 3834946. DOI: 10.3390/pharmaceutics5020261. View

11.

Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B . Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014; 69(5):1362-9. DOI: 10.1093/jac/dkt532. View

12.

Johnson A, Edson K, Totah R, Rettie A . Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer. Adv Pharmacol. 2015; 74:223-62. PMC: 4667791. DOI: 10.1016/bs.apha.2015.05.002. View

13.

Qi H, Lu J, Li J, Wang M, Xu Y, Wang Y . Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation. J Pharm Sci. 2016; 105(9):2966-2973. DOI: 10.1016/j.xphs.2016.02.006. View

14.

Murakami E, Tolstykh T, Bao H, Niu C, Micolochick Steuer H, Bao D . Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010; 285(45):34337-47. PMC: 2966047. DOI: 10.1074/jbc.M110.161802. View

15.

Kalsotra A, Strobel H . Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol Ther. 2006; 112(3):589-611. DOI: 10.1016/j.pharmthera.2006.03.008. View

16.

Wang M, Wu J, Bridges A, Zeldin D, Kornbluth S, Tidwell R . Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos. 2007; 35(11):2067-75. PMC: 2364724. DOI: 10.1124/dmd.107.016428. View

17.

Mehellou Y, Rattan H, Balzarini J . The ProTide Prodrug Technology: From the Concept to the Clinic. J Med Chem. 2017; 61(6):2211-2226. PMC: 7075648. DOI: 10.1021/acs.jmedchem.7b00734. View

18.

Sofia M, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S . Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010; 53(19):7202-18. DOI: 10.1021/jm100863x. View

19.

Dubey R, Saneja A, Gupta P, Gupta P . Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine. Eur J Pharm Sci. 2016; 93:147-62. DOI: 10.1016/j.ejps.2016.08.021. View

20.

Andrews L, Zalatan J, Herschlag D . Probing the origins of catalytic discrimination between phosphate and sulfate monoester hydrolysis: comparative analysis of alkaline phosphatase and protein tyrosine phosphatases. Biochemistry. 2014; 53(43):6811-9. PMC: 4222534. DOI: 10.1021/bi500765p. View